Newcastle disease virus vectored avian vaccines
View Patent ↗The present invention encompasses engineered Newcastle Disease Virus (NDV) vaccines or compositions. The vaccine or composition may be a recombinant vaccine. The invention also encompasses recombinant vectors encoding and expressing avian pathogen antigens, more specifically avian influenza proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals, in particular avian, against disease.
1. An engineered NDV vector comprising a polynucleotide, wherein the polynucleotide has at least 97% sequence identity to SEQ ID NO:1 or is complementary to a polynucleotide having at least 97% sequence identity to SEQ ID NO:1, and wherein the NDV vector further comprises a heterologous polynucleotide encoding an avian influenza hemagglutinin (HA) antigen, and wherein the HA antigen has the sequence as set forth in SEQ ID NO:15, 17, 19, 21 or 23.
2. The NDV vector of claim 1 , wherein the polynucleotide has at least 98% sequence identity to SEQ ID NO:1, or is complementary to a polynucleotide having at least 98% sequence identity to SEQ ID NO:1.
3. The NDV vector of claim 1 , wherein the polynucleotide has at least 99% sequence identity to SEQ ID NO:1, or is complementary to a polynucleotide having at least 99% sequence identity to SEQ ID NO:1.
4. The NDV vector of claim 1 , wherein the polynucleotide has the sequence as set forth in SEQ ID NO:1, or is complementary to a polynucleotide having the sequence as set forth in SEQ ID NO:1.
5. The NDV vector of claim 1 , wherein the heterologous polynucleotide has the sequence as set forth in SEQ ID NO:14, 16, 18, 20, or 22.
6. The NDV vector of claim 1 , wherein the HA antigen has the sequence as set forth in SEQ ID NO:15.
7. The NDV vector of claim 1 , wherein the HA antigen has the sequence as set forth in SEQ ID NO:17.
8. The NDV vector of claim 1 , wherein the HA antigen has the sequence as set forth in SEQ ID NO:19.
9. The NDV vector of claim 1 , wherein the HA antigen has the sequence as set forth in SEQ ID NO:21.
10. The NDV vector of claim 1 , wherein the HA antigen has the sequence as set forth in SEQ ID NO:23.
11. A composition comprising an engineered Newcastle Disease Virus (NDV) vector, wherein the engineered NDV vector comprises a polynucleotide having at least 97% sequence identity to a polynucleotide having the sequence as set forth in SEQ ID NO:1 or a polynucleotide complementary to a polynucleotide having at least 97% sequence identity to the polynucleotide having the sequence as set forth in SEQ ID NO:1, and wherein the engineered NDV vector further comprises a heterologous polynucleotide encoding an avian influenza hemagglutinin (HA) antigen, and wherein the HA antigen has the sequence as set forth in SEQ ID NO:15, 17, 19, 21 or 23.
12. The composition of claim 11 , wherein the heterologous polynucleotide has the sequence as set forth in SEQ ID NO:14, 16, 18, 20, or 22.
13. The composition of claim 11 , wherein the polynucleotide has at least 98% sequence identity to SEQ ID NO:1, or is complementary to a polynucleotide having at least 98% sequence identity to SEQ ID NO:1.
14. The composition of claim 11 , wherein the polynucleotide has at least 99% sequence identity to SEQ ID NO:1, or is complementary to a polynucleotide having at least 99% sequence identity to SEQ ID NO:1.
15. The composition of claim 11 , wherein the polynucleotide has the sequence as set forth in SEQ ID NO:1, or is complementary to a polynucleotide having the sequence as set forth in SEQ ID NO:1.
16. The composition of claim 11 , wherein the HA antigen has the sequence as set forth in SEQ ID NO:15.
17. The composition of claim 11 , wherein the HA antigen has the sequence as set forth in SEQ ID NO:17.
18. The composition of claim 11 , wherein the HA antigen has the sequence as set forth in SEQ ID NO:19.
19. The composition of claim 11 , wherein the HA antigen has the sequence as set forth in SEQ ID NO:21.
20. The composition of claim 11 , wherein the HA antigen has the sequence as set forth in SEQ ID NO:23.